United States $4.6 Billion Biopharmaceutical Royalty Aggregator Company Ligand Pharmaceuticals Buys United States Biotechnology Royalty Aggregator XOMA Royalty for $739 Million in All-Cash Deal (With Additional Net Proceeds from Janssen Biotech Litigation), XOMA Royalty Founded in 1981 by Patrick J. Scannon as Xoma Ltd., XOMA Royalty Current Market Value at $501.9 Million, Share Price +55.6% YTD, +76.5% Last 12 Months & +8.7% Last 5 Years
2nd May 2026 | Hong Kong
United States biopharmaceutical royalty aggregator company Ligand Pharmaceuticals ($4.6 billion market value) has announced to buy United States biotechnology royalty aggregator XOMA Royalty for $739 million in all-cash deal (With additional net proceeds from Janssen Biotech litigation). XOMA Royalty was founded in 1981 by Patrick J. Scannon as Xoma Ltd. XOMA Royalty current market value at $501.9 million, share price +55.6% YTD, +76.5% last 12 months & +8.7% last 5 years. XOMA Royalty – XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). Ligand Pharmaceuticals – Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines.
“ United States $4.6 Billion Biopharmaceutical Royalty Aggregator Company Ligand Pharmaceuticals Buys United States Biotechnology Royalty Aggregator XOMA Royalty for $739 Million in All-Cash Deal (With Additional Net Proceeds from Janssen Biotech Litigation), XOMA Royalty Founded in 1981 by Patrick J. Scannon as Xoma Ltd., XOMA Royalty Current Market Value at $501.9 Million, Share Price +55.6% YTD, +76.5% Last 12 Months & +8.7% Last 5 Years “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
United States $4.6 Billion Biopharmaceutical Royalty Aggregator Company Ligand Pharmaceuticals Buys United States Biotechnology Royalty Aggregator XOMA Royalty for $739 Million in All-Cash Deal (With Additional Net Proceeds from Janssen Biotech Litigation), XOMA Royalty Founded in 1981 by Patrick J. Scannon as Xoma Ltd., XOMA Royalty Current Market Value at $501.9 Million, Share Price +55.6% YTD, +76.5% Last 12 Months & +8.7% Last 5 Years
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
